It’s far from clear that the EU and U.S. will be able to iron out all their differences on the many contentious issues yet to deal with.

With global trade frictions and rapid policy shifts set to continue, companies can no longer afford to treat tariffs as a short-term challenge

A number of other drugmakers have rolled out similar plans to ramp up U.S. manufacturing in recent days, in the face of continued pressure from the Trump administration.

Even traditional automation of assigning HS codes, in the form of digitally stored and searchable codes, is of limited utility. Enter artificial intelligence.

Switzerland is a major exporter of drugs to the U.S., with pharmaceuticals accounting for almost half of Swiss goods exports to America in 2024.

The analysis is among the first to measure the direct costs created by the import taxes on employers with $10 million to $1 billion in annual revenue.

A case study about implementing a new inventory-reduction solution, with Allan Jaenicke, vice president of strategy and operational excellence with Waters Corp., and Carrie Brown, transformation evangelist with Celonis.

A discussion about innovation in product development and the supply chain, with Joe Bitterman, VP supply chain planning with Johnson & Johnson Innovative Medicine, and Philip Vervloesem, chief commercial officer with OMP.

Michael Halaiko and Alex Moylan, shareholders in the law firm of Baker Donelson, discuss the Trump Administration’s recent executive orders on domestic production of critical medicines.

However, analysts warn that a prolonged trade war could produce lasting macroeconomic impacts on the country.